Penn-Led Consortium to Advance Imaging of Brain Diseases
New Imaging Technique Could Revolutionize Parkinson’s Diagnosis adn Treatment
Researchers at Penn Medicine are leading a nationwide effort to develop groundbreaking imaging techniques for Parkinson’s disease and other neurodegenerative disorders.
This innovative approach utilizes positron emission tomography (PET) scans and specially designed radioactive tracers to illuminate specific proteins in the brain associated with these diseases. The project, funded by a $30 million grant from the National Institutes of Neurological Disease and Stroke, brings together experts from across the country in a collaborative “Centre Without Walls.”
“Due to the sheer number of possible molecules that could be used,the process of developing new radiotracers has been slow and intricate,” said Dr. Robert Mach, the Britton Chance Professor of radiology at Penn Medicine, who is leading the project. “Our Center Without Walls combines clinical, scientific, imaging, and computational expertise from across institutions to develop a creative solution for this problem.”
targeting the Culprits: α-Synuclein and 4R Tau
The team is focusing on developing two distinct radiotracers: one that binds to α-synuclein (αSyn), a protein implicated in Parkinson’s disease and multiple system atrophy, and another that targets 4R tau, a protein linked to frontotemporal degeneration and progressive supranuclear palsy.
These diseases, known as “proteinopathies,” are characterized by the misfolding and aggregation of specific proteins in the brain. By visualizing these protein buildups with PET scans, researchers hope to achieve earlier and more accurate diagnoses, track disease progression over time, and monitor the effectiveness of treatments.
A Computational Breakthrough
A key innovation in this project is the progress of a powerful computational chemistry tool by Dr. E. James petersson and his team at the University of Pennsylvania’s Department of Chemistry. This tool sifts through millions of potential molecules, identifying a select few with the highest likelihood of binding effectively to the target proteins.Using this method, the team has already narrowed down the field to three promising candidates: two for αSyn and one for 4R tau.Clinical trials of these tracers in human subjects are set to begin in the coming years.
Transforming Diagnosis and Treatment
The potential impact of this research is immense.
“Now that we’ve shown this computational chemistry model can identify the right molecules to bind to and trace αSyn, our hope is that soon we can plug any protein target into the model and rapidly develop an effective radiotracer,” said Dr. Mach. “This could get these tracers into clinics sooner, so that we can better diagnose and manage a range of complicated diseases.”
If successful, this project could revolutionize the way we approach neurodegenerative diseases, offering earlier diagnosis, more precise monitoring, and ultimately, the development of more effective treatments.
New imaging Technique Could Revolutionize Parkinson’s Diagnosis and Treatment
Philadelphia, PA – A pioneering national effort led by researchers at Penn Medicine promises to transform our understanding and treatment of Parkinson’s disease and other neurodegenerative disorders.
This groundbreaking initiative utilizes a combination of positron emission tomography (PET) scans and specially designed radioactive tracers to pinpoint specific proteins in the brain associated with these debilitating diseases.
Fueled by a $30 million grant from the National Institutes of Neurological Disease and Stroke, this collaborative “Center Without Walls” brings together leading experts from across the country.
“The development of new radiotracers has been a slow and intricate process due to the sheer number of potential molecules,” explains Dr. Robert Mach, the Britton Chance Professor of Radiology at Penn Medicine and the project leader. “Our Center Without Walls combines clinical, scientific, imaging, and computational expertise from across institutions to develop a creative solution for this problem.”
Targeting the Culprits:
The research team is laser-focused on developing two distinct radiotracers: one that binds to α-synuclein (αSyn), a protein implicated in parkinson’s disease and multiple system atrophy, and another that targets 4R tau, a protein linked to frontotemporal degeneration and progressive supranuclear palsy. These proteinopathies are characterized by the misfolding and aggregation of specific proteins in the brain.
By visualizing these abnormal protein buildups with PET scans, researchers anticipate achieving earlier and more accurate diagnoses, tracking disease progression over time, and monitoring the effectiveness of treatments.
A Computational Breakthrough:
A key innovation driving this project is the development of a powerful computational chemistry tool by Dr. E.James Petersson and his team at the University of Pennsylvania’s Department of Chemistry. This tool analyzes millions of potential molecules,identifying those with the highest probability of effectively binding to the target proteins.
Using this method,the team has already narrowed their focus to three promising candidates: two for αSyn and one for 4R tau. Clinical trials of these tracers in human subjects are scheduled to commence in the coming years.
Transforming Diagnosis and treatment:
The potential impact of this research is monumental.
“Now that we’ve demonstrated the ability of this computational chemistry model to identify molecules that can bind to and trace αSyn, our hope is that we can soon plug any protein target into the model and rapidly develop an effective radiotracer,” says Dr. Mach. “This could expedite the introduction of these tracers into clinical settings, enabling us to better diagnose and manage a range of complex diseases.”
if successful, this project has the potential to revolutionize how we approach neurodegenerative diseases, paving the way for earlier diagnosis, more precise monitoring, and ultimately, the development of more effective therapies.